Gaugler B, Olive D
Institut Paoli-Calmettes, Marseille, France.
Pathol Biol (Paris). 1998 Dec;46(10):771-8.
The melanoma antigen coded by the MAGE-1 gene was the first tumor antigen described in human cancer. Genetic, biochemical, and "candidate peptide" strategies have been used to identify antigenic peptides presented to T-cells by class I major histocompatibility complex antigens. Antigens have now been characterized in a wide variety of tumor types. Five categories have been described based on expression profile. These antigens are detailed in this review. Among the tumor antigens produced as a result of intratumoral mutations, some are of special interest because of their potentially oncogenic effects. These new data can be expected to lead to the development of novel anticancer treatments based on specific immunotherapy. Pilot clinical studies are ongoing.
由MAGE-1基因编码的黑色素瘤抗原是在人类癌症中描述的首个肿瘤抗原。遗传、生化和“候选肽”策略已被用于识别由I类主要组织相容性复合体抗原呈递给T细胞的抗原肽。目前已在多种肿瘤类型中对抗原进行了表征。根据表达谱描述了五类。本综述对这些抗原进行了详细阐述。在因肿瘤内突变而产生的肿瘤抗原中，有些因其潜在的致癌作用而特别引人关注。这些新数据有望促成基于特异性免疫疗法的新型抗癌治疗方法的开发。先导性临床研究正在进行中。
